Kaléo Inc. said on Wednesday that it will relaunch its Auvi-Q injector for emergency allergy treatment in the 1st half of 2017 in the U.S., according to Reuters.
The Richmond, Virginia-based company’s device was recalled last year after concerns about the accuracy of delivered dose. Sanofi (NYSE:SNY) made and licensed the Auvi-Q device from Kaléo, but returned rights to the product in February following the recall.
Get the full story at our sister site, Drug Delivery Business News.